Диссертация (1139975), страница 16
Текст из файла (страница 16)
А. Рекомендации для фармацевтических компаний по изучениюбиотрансформации и транспортеров новых лекарственных средств: дизайн110исследований, анализ данных и внесение информации в инструкции поприменению/науч.ред.В.Г.Кукес.—М,2009.URL:http://www.regmed.ru/Content/Doc.aspx?id=26a9128c-ee32-4469-9c645c666339049e (доступ от: 20.12.2015)24.Сычев Д.А., Раменская Г.В., Игнатьев И.В., Кукес В.Г. Клиническаяфармакогенетика.
- М.: ГЭОТАР-Медиа, 2007. – 50 с.25.Фрейдин М.Б., Брагина М.Ю., Петровский Ф.И., идр. Анализ связиполиморфизма генов GSTT1, GSTM1, CYP2C19, CYP2E1с атопией у жителейг. Томска. Медицинская иммунология 2003; 1-2:107-11226.Халикова А.Р., Архипова А.А., Ахметов И.И. и др. Изучение полиморфизмагена цитохрома Р-450 CYP2C19 в популяции татар, проживающих натерритории Республики Татарстан. Практическая медицина 2012; 3(58):53-55.27.Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity oncardiovascular outcomes in patients with type 2 diabetes mellitus and coronaryartery disease // J Am Coll Cardiol. – 2007. – Vol. 50.
– P. 1541–1547.28.Aradi D, Komócsi A, Price MJ, et al. Efficacy and safety of intensifiedantiplatelet therapy on the basis of platelet reactivity testing in patients afterpercutaneous coronary intervention: systematic review and meta-analysis // Int JCardiol. – 2013. - Vol. 167. – P. 2140–2148.29.Aradi D, Komocsi A, Vorobcsuk A, et al.
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematicreview and meta-analysis // Am Heart J. – 2010. - Vol. 160. – P. 543-551.30.Aradi D, Pinte´r T, Magyari B, et al. Optimizing P2Y12-receptor inhibitionin acute coronary syndrome patients after PCI using platelet function testing:impact of prasugrel versus high-dose clopidogrel // J Am Coll Cardiol. – 2013. Vol. 61. -Supl. A477.11131.Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role ofplatelet function testing in patients undergoing percutaneous coronary intervention// Eur Heart J. – 2014.
- Vol. 35. – P. 209–215.32.Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects // Drug Discov Today. – 2007. Vol. 12. – P. 838–843.33.Barden A, Beilin L, Croft L, et al. The influence of a single nucleotidepolymorphism in the CYP4F2 gene on platelet epoxyeicosatrienoic acids andplatelet aggregation // The 11th Biennial ISSFAL Congress 2014; 2014 June 28 –July; Stockholm, Sweden.
URL: http://issfal2014.conferencespot.org/53974-ha1.1180093/t-002-1.1181977/f-020-1.1182049/a-019-1.1182050/ap-082-1.1182054(Accessed 09.02. 2014).34.Beitelshees AL, Horenstein RB, Vesely MR, et al. Pharmacogenetics andclopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther. – 2011. - Vol. 89. – P. 455–459.35.Bernlochner I, Steinhubl S, Braun S, et al. Association betweeninflammatory biomarkers and platelet aggregation in patients under chronicclopidogrel treatmen // Thromb Haemost. – 2010. - Vol. 104.
– P. 1193–1200.36.Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences betweennative Chinese and Swedish populations in the polymorphic hydroxylation ofdebrisoquine and S-mephenytoin // Clin Pharmacol Ther. – 1992. - Vol. 51. –P.388–397.37.Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinesehamster cells in vitro: crossresistance, radioautographic, and cytogenetic studies //Cancer Res. – 1970. - Vol.
30. – P. 1174–1184.11238.Björkhem-Bergman L, Bäckström T, Nylén H, et al. Comparison ofendogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4induction by rifampicin // Drug Metab Dispos. – 2013. - Vol. 41. – P. 1488-1493.39.Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading doseadjustment according to platelet reactivity monitoring in patients carrying the2C19*2 loss of function polymorphism // J Am Coll Cardiol.
– 2010. - Vol. 56. –P.1630-1636.40.Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading doseaccording to platelet reactivity monitoring to prevent acute and subacute stentthrombosis // Am J Cardiol. – 2009. - Vol. 103. – P. 5–10.41.Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions onthe definition of high on-treatment platelet reactivity to adenosine diphosphate // JAm Coll Cardiol. – 2010. - Vol. 56.
– P. 919–933.42.Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a majordeterminant of clopidogrel efficacy // Nat Med. - 2011. - Vol. 17. – P. 110–116.43.Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19and CYP2C9 affect the pharmacokinetic and pharmacodynamic response toclopidogrel but not prasugrel // J Thromb Haemost.
– 2007. - Vol. 5. – P. 2429–2436.44.Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity onclinical outcomes after percutaneous coronary intervention. A collaborative metaanalysis of individual participant data // J Am Coll Cardiol. – 2011. - Vol. 58. –P. 1945–1954.45.Braun OO, Angiolillo DJ, Ferreiro JL et al. Enhanced active metabolitegeneration and platelet inhibition with prasugrel compared to clopidogrel regardless113of genotype in thienopyridine metabolic pathways // Thromb Haemost. – 2013.
Vol. 110. – P. 1223–1231.46.Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of plateletfunction tests in predicting clinical outcome in patients undergoing coronary stentimplantation // JAMA. – 2010. - Vol. 303. – P. 754–762.47.Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transportergene MDR1 // Pharmacogenomics J. – 2001.
- Vol. 1. - P. 59–64.48.Brøsen K, de Morais SM, Meyer UA, et al. A multifamily study on therelationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype //Pharmacogenetics. – 1995. - Vol. 5. – P. 312-317.49.Brunton, L. L. Goodman and Gilman's The Pharmacological Basis ofTherapeutics, Twelfth Edition/ L. L.
Brunton, B.A. Chabner, B.C. Knollmann eds. New York: McGraw-Hill, 2011. - 2048 P.50.Caciagli L, Bulayeva K, Bulayev O, et al. The key role of patrilinealinheritance in shaping the genetic variation of Dagestan highlanders // J HumGenet. – 2009. - Vol. 54. – P. 689-69451.Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneouscoronary intervention relationship with gene polymorphisms and clinical outcome //J Am Coll Cardiol.
– 2011. - Vol. 57. – P. 2474–2483.52.Cannon CP, Harrington RA, James S, et al., Comparison of ticagrelor withclopidogrel in patients with a planned invasive strategy for acute coronarysyndromes (PLATO): a randomised double-blind study // Lancet. – 2010. - Vol.375. –P. 283–29311453.Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects ofdifferent aspirin dosing regimens in type 2 diabetesmellitus patients with coronaryartery disease // Circ Cardiovasc Interv. – 2011. - Vol. 4.
– P. 180–187.54.Capranzano P, Tamburino C, Capodanno D, et al. Platelet function profilesin the elderly: results of a pharmacodynamic study in patients on clopidogreltherapy and effects of switching to prasugrel 5 mg in patients with high plateletreactivity // Thromb Haemost. – 2011. - Vol. 106. – P. 149–157.55.Cayla G, Cuisset T, Silvain J, et al. Prasugrel monitoring and bleeding in realworld patients // Am J Cardiol. – 2013. - Vol.
111. – P. 38–44.56.Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and geneticfactors associated with early coronary stent thrombosis // JAMA. – 2011. - Vol.306. – P. 1765–1774.57.Chang M, Dahl ML, Tybring G, et al. Use of omeprazole as a probe drug forCYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoinhydroxylation phenotype and CYP2C19 genotype // Pharmacogenetics. – 1995. Vol. 5. – P.
358-363.58.Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association betweenbleeding events and in-hospital mortality after percutaneous coronary intervention //JAMA. – 2013. - Vol. 309. – P. 1022–102959.Choi SW, Choi DH, Kim HW et al. Clinical outcome prediction from meanplatelet volume in patients undergoing percutaneous coronary intervention inKorean cohort: Implications of more simple and useful test than platelet functiontesting // Platelets. – 2014. - Vol. 25. – P. 322-327.60.Chu SG, Becker RC, Berger PB, et al.
Mean platelet volume as a predictor ofcardiovascular risk: a systematic review and meta-analysis // J Thromb Haemost. –2010. - Vol. 8. – P. 148–156.11561.Clinton P, Mozeson M. Pharma Exec 50. Pharmaceutical Executive Magazine. –2010. – P. 70–80. URL:http://images.alfresco.advanstar.com/alfresco_images/pharma/2014/08/20/eaac2a05-db6c-4198-86ef-a9e67de006a5/article-820593.pdf (accessed 12.09.
2014).62.Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelettherapy for coronary stenting // N Engl J Med. – 2012. - Vol. 367. – P. 2100–2109.63.Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism inyoung patients treated with clopidogrel after myocardial infarction: a cohort study //Lancet.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
